Fresenius SE & Co KGaA 2017 AR2
The report highlights Fresenius' strong performance in fiscal year 2017, with sales crossing the ’30 billion mark for the first time, reaching ’33,886 million. The company expanded its international presence through the strategic acquisition of Quirónsalud, Spain's largest private hospital operator, and Merck KGaA's biosimilars business. In addition, Fresenius published its first separate Group Nonfinancial Report, emphasizing its commitment to patient well-being, quality of care, and compliance. The company also proposed its 25th consecutive dividend increase, reflecting its sustained financial growth.
Company: Fresenius SE & Co KGaA
Sector: Manufacturing
Country: Germany
Year: 2017
Type: AR2
Pages: 247
Back to company
Fresenius SE & Co KGaA
Annual Report
The report highlights Fresenius' strong performance in fiscal year 2017, with sales crossing the ’30 billion mark for the first time, reaching ’33,886 million. The company expanded its international presence through the strategic acquisition of Quirónsalud, Spain's largest private hospital operator, and Merck KGaA's biosimilars business. In addition, Fresenius published its first separate Group Nonfinancial Report, emphasizing its commitment to patient well-being, quality of care, and compliance. The company also proposed its 25th consecutive dividend increase, reflecting its sustained financial growth.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2017
Reporting Period
Jan 1, 2017 - Dec 31, 2017
Fiscal Year
2017
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Water Consumption
Women in Management
Employees